Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection by Zhang, Weidong et al.
ORIGINAL RESEARCH
published: 19 June 2020
doi: 10.3389/fimmu.2020.01246








Vicente de Paulo Martins,
University of Brasilia, Brazil
Barbara Castro-Pimentel Figueiredo,




†These authors have contributed
equally to this work and share first
authorship
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology
Received: 15 March 2020
Accepted: 18 May 2020
Published: 19 June 2020
Citation:
Zhang W, Le L, Ahmad G, Molehin AJ,
Siddiqui AJ, Torben W, Karmakar S,
Rojo JU, Sennoune S, Lazarus S,
Khatoon S, Freeborn J, Sudduth J,
Rezk AF, Carey D, Wolf RF, Papin JF,
Damian R, Gray SA, Marks F, Carter D
and Siddiqui AA (2020) Fifteen Years
of Sm-p80-Based Vaccine Trials in
Nonhuman Primates: Antibodies From
Vaccinated Baboons Confer
Protection in vivo and in vitro From
Schistosoma mansoni and




Fifteen Years of Sm-p80-Based
Vaccine Trials in Nonhuman
Primates: Antibodies From
Vaccinated Baboons Confer
Protection in vivo and in vitro From
Schistosoma mansoni and
Identification of Putative Correlative
Markers of Protection
Weidong Zhang 1,2†, Loc Le 1,2†, Gul Ahmad 3, Adebayo J. Molehin 1,2, Arif J. Siddiqui 4,
Workineh Torben 5, Souvik Karmakar 6, Juan U. Rojo 7, Souad Sennoune 1,2,
Samara Lazarus 1,2, Sabiha Khatoon 1,2, Jasmin Freeborn 1,2, Justin Sudduth 1,2,
Ashraf F. Rezk 1,2, David Carey 8, Roman F. Wolf 8,9, James F. Papin 8, Ray Damian 10,
Sean A. Gray 11, Florian Marks 12,13, Darrick Carter 11,14 and Afzal A. Siddiqui 1,2*
1Center for Tropical Medicine and Infectious Diseases, Texas Tech University Health Sciences Center, Lubbock, TX,
United States, 2Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center,
Lubbock, TX, United States, 3Department of Natural Sciences, Peru State College, Peru, NE, United States, 4Department of
Biology, University of Hail, Hail, Saudi Arabia, 5Department of Biological Sciences, Louisiana State University of Alexandria,
Alexandria, LA, United States, 6Center for Cancer Research, National Cancer Institute, National Institutes of Health,
Bethesda, MD, United States, 7Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire,
Durham, NH, United States, 8Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK,
United States, 9Oklahoma City VA Health Care System, Oklahoma City, OK, United States, 10Department of Cellular Biology,
University of Georgia, Athens, GA, United States, 11 PAI Life Sciences, Seattle, WA, United States, 12 International Vaccine
Institute, SNU Research Park, Seoul, South Korea, 13Department of Medicine, University of Cambridge, Cambridge,
United Kingdom, 14 Infectious Disease Research Institute, Seattle, WA, United States
Recent advances in systems biology have shifted vaccine development from a
largely trial-and-error approach to an approach that promote rational design through
the search for immune signatures and predictive correlates of protection. These
advances will doubtlessly accelerate the development of a vaccine for schistosomiasis,
a neglected tropical disease that currently affects over 250 million people. For
over 15 years and with contributions of over 120 people, we have endeavored
to test and optimize Sm-p80-based vaccines in the non-human primate model of
schistosomiasis. Using RNA-sequencing on eight different Sm-p80-based vaccine
strategies, we sought to elucidate immune signatures correlated with experimental
protective efficacy. Furthermore, we aimed to explore the role of antibodies through
in vivo passive transfer of IgG obtained from immunized baboons and in vitro killing
of schistosomula using Sm-p80-specific antibodies. We report that passive transfer of
IgG from Sm-p80-immunized baboons led to significant worm burden reduction, egg
reduction in liver, and reduced egg hatching percentages from tissues in mice compared
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to controls. In addition, we observed that sera from Sm-p80-immunized baboons were
able to kill a significant percent of schistosomula and that this effect was complement-
dependent. While we did not find a universal signature of immunity, the large datasets
generated by this study will serve as a substantial resource for further efforts to develop
vaccine or therapeutics for schistosomiasis.
Keywords: Schistosoma mansoni, schistosomiasis, baboons, Sm-p80 vaccine, systems biology, transcriptomics,
passive transfer
INTRODUCTION
Schistosomiasis is a debilitating neglected tropical disease caused
by infection with parasitic trematodes of the genus Schistosoma.
Six species of Schistosoma cause clinical disease in humans,
altogether responsible for over 290,000 deaths annually (1).
While the rate of mortality is relatively low considering over
250 million people live with this disease (2), the clinical
manifestations of schistosomiasis are chronic and insidious,
including anemia, growth retardation, fever, genital lesions,
hepatosplenomegaly and slow, irreversible organ damage (3,
4). These sequelae result in 3.31 million disability-adjusted life
years (DALYS) lost according to recent estimates (5). Currently,
schistosomiasis is endemic in 78 countries with over 800 million
people at risk for infection (6).
For a myriad of reasons, control and elimination of
schistosomiasis have eluded the research community and policy
makers alike. While some success in reducing the spread of
this disease have been achieved through integrated approaches
combining mass drug administration (MDA), molluscicides,
health education, behavior modification, and public works
programs such as construction of concrete irrigation canals,
schistosomiasis continues to be a major source of global health
burden (7–9). Implementation of these integrated interventions
can be logistical questions in economically strained communities
such as rural villages in sub-Saharan Africa and southeast
Asia (10, 11). It is within these communities, especially in
high transmission hotspots, that MDA alone cannot result in
the elimination of schistosomiasis as a public health concern
(12). While mathematical modeling on the effectiveness of
praziquantel (PZQ), the drug of choice used for antischistosome
MDA, predicts against the emergence of drug resistance
in the near future, overreliance and widespread repeated
administration of PZQ may result in that future sooner rather
than later (13, 14). Additionally, PZQ is not effective against
juvenile schistosome parasites and does not prevent re-infection,
necessitating repeated rounds of MDA for schistosomiasis
control and elimination initiatives. Lapses in MDA can lead to
rapid rebound of community infection rates to pre-treatment
levels (15, 16). Hence, development of an antischistosome vaccine
would be beneficial to achieve schistosomiasis elimination
goals (17–19).
Sm-p80 is the large subunit of a schistosome calcium-
activated neutral protease calpain (20), and has been tested for its
vaccine efficacy in different vaccine strategies and formulations
since 1997 (21). Although Sm-p80-based vaccines have been
demonstrated to havemany beneficial effects such as prophylactic
(22) and therapeutic efficacy (23), cross-species protection
against S. haematobium (24) and S. japonicum (25), immune
correlates and mechanisms of protection against schistosomiasis
remain poorly understood. While much has been learned from
conventional immunological methods such as ELISA, Western
blotting, ELISPOT, and even flow cytometry, recent development
in systems biology and high throughput “omics” technologies
have invited large paradigm shifts to vaccinology (26, 27). Using
next-generation RNA sequencing (RNA-Seq), our group has
reported some key molecular gene interactions associated with
Sm-p80-based vaccine immunogenicity and efficacy (28, 29) as
well as system-widemolecular interactions associated with trickle
schistosome infections, chronic disease and PZQ treatment in
the nonhuman primate model (29). In the present study, we
aimed to explore immune signatures of Sm-p80-based vaccines
through transcriptomic analyses of eight different strategies
utilized across 15 years of preclinical studies using the baboon
model, correlating with previously published efficacy results.
Furthermore, we assessed the role of antibodies through in vivo
passive transfer of IgG obtained from immunized baboons and in
vitro killing of schistosomula using Sm-p80-specific antibodies.
MATERIALS AND METHODS
Statement of Ethics
All animal procedures were conducted in accordance with
Institutional Animal Care and Use Committee (IACUC)
Guidelines (Protocol Number 20010202) and were approved
by the Animal Ethics Committee at the Texas Tech University
Health Sciences Center.
Animals and Parasites
Female C57BL/6 mice (6–8 weeks old) were purchased from
Charles River Laboratories (Wilmington,MA, USA). Schistosoma
mansoni (Puerto Rico PR-1 strain)-infected Biomphalaria
glabrata snails were procured from the Schistosome Resources
Center (Biomedical Research Institute, Rockville, MD, USA).
Source of Sera, IgG, and Cells
The sera used for heterologous passive transfer experiments were
obtained from pooled sera of baboons immunized with Sm-
p80-based vaccines and their control counterparts from eight
previous studies. First, Sm-p80-VR1020 was a DNA vaccine
formulation which elicited a robust antibody response and Th1-
related cytokines such as interferon-gamma (IFNγ) (22). The
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second and third Sm-p80-based vaccine strategies used in this
study were DNA prime with Sm-p80-VR1020 and protein boost
with recombinant Sm-p80 and CpG ODN10104 (TLR9 agonist)
or Resiquimod (TLR7 agonist) (30), yielding a nuanced and
balanced pro-inflammatory and anti-inflammatory response as
well as high IgG titers. The fourth and fifth strategies from which
samples were obtained in this study were recombinant Sm-p80
formulated with CpG ODN10104 (TLR9 agonist) or Resiquimod
(30), producing a similar immune response profile yet resulting
in higher protection compared to the prime-boost counterparts.
Finally, the sixth, seventh, and eighth vaccine strategies were
recombinant Sm-p80 formulated with glucopyranosyl lipid
adjuvant (GLA) as an aqueous formulation (AF), formulated
with aluminum hydroxide (Alum), or formulated in a soluble
oil-in-water emulsion (SE). Recombinant Sm-p80 formulated
with GLA-SE (31) demonstrated the highest levels of protection
while GLA-AF (unpublished data) and GLA-Alum (32) did
not surpass previously tested strategies. These eight vaccination
strategies followed a standard immunization schedule with 3-
4 injections at 4-week intervals followed by parasite challenge
with 1000 S. mansoni cercariae 4 weeks after the final injection.
Eight weeks after parasite challenge, animals were sacrificed
and adult worms were perfused from the portal system
and mesenteric veins. Blood was collected after vaccination
(to determine the effect of the vaccine), and 8 weeks after
parasite challenge (to study vaccine-induced immune responses
with schistosomiasis disease progression). Blood was also
collected from animals in their respective control groups which
received adjuvant control injections in place of the vaccine.
Spleen and mesenteric lymph nodes samples were collected
at necropsy.
IgG was purified from baboon sera pooled from all 8
aforementioned strategies using PierceTM Protein A/G
Agarose kit (Thermo Fisher Scientific) according to
manufacturer’s protocol. IgG purity was analyzed by SDS-
PAGE and concentration was measured by NanoDrop 1000
Spectrophotometer (Thermo Fisher Scientific). Peripheral blood
mononuclear cells (PBMCs) from two time points, spleen cells,
and mesenteric lymph nodes from the eight Sm-p80-based
vaccine strategies and their respective controls were previously
stored in freezing media (10% DMSO in fetal bovine sera and
RPMI) at −80◦C and were used for transcriptomic analyses
via RNA-seq.
Heterologous Passive Transfer and
Parasite Challenge
Twenty C57BL/6 mice were randomly divided into control (n
= 10) and experimental (n = 10) groups. Each mouse from
the control group received an intravenous injection of purified
IgG (75 µg) from control baboon sera while those in the
experimental group received purified IgG (75 µg) from Sm-p80-
immunized baboon sera at days 0, 3, and 9. At day 6, each mouse
was challenged with 150 Schistosoma mansoni cercariae via tail
immersion in water to allow for percutaneous infection. Two
of the control mice died over the course of this study due to
unknown reasons and were excluded from analysis.
Determination of Worm Burden, Egg
Burden, and Tissue Egg Hatching
Mice were euthanized six weeks post-cercarial challenge and
adult worms were recovered from the mesenteric vasculature and
hepatic portal system by perfusion (33). The percent reduction in
adult worm burden was determined by comparing the number of
worms recovered from the experimental groups (I) to the control
group (C). Protection (P) was calculated using the formula: %P
= [(C – I)/C × 100]. To assess the schistosome egg burden
in tissues, livers and intestines of the euthanized mice were
digested in 4% potassium hydroxide at 37◦C overnight without
CO2, washed, and resuspended in a 1.2% (w/v) sodium chloride
solution (33). Eggs were enumerated under light microscopy to
determine the number of eggs per gram in liver and intestine.
Tissue egg hatching rates were determined as previously
described (29). Briefly, 0.5–1 g sections of liver and intestine
were collected from each mouse following euthanasia. Tissue
samples were placed in a solution of cold 1.2% NaCl and gently
homogenized with a blender for 30 s. The homogenized samples
were then passed through a series of sieves (180, 106, and 45µm
mesh opening). Schistosoma mansoni eggs were collected from
the 45µm sieve and centrifuged at 300 × g for 10min. The
egg pellet was resuspended in fresh water after discarding the
supernatant and seeded into 24-well plates. These plates were
placed under a light source for 2 h to induce egg hatching. Mature
eggs and hatched eggs were counted using a light microscope and
the egg hatching rates were expressed as the percentage of eggs
hatched compared to mature eggs.
In vitro Killing of Schistosoma mansoni
Schistosomula
Sera for in vitro schistosomula killing assay were obtained
as described above. Schistosoma mansoni cercariae collected
from infected snails were mechanically transformed into
schistosomula by repeated transfers through a 22 gauge syringe
needle (33). Approximately 50 schistosomula were seeded
into each well of a 24-well plate and cultured overnight in
complete media (RPMI 1640 supplemented with 10% fetal
bovine serum, 100µg/mL penicillin G, 100µg/mL streptomycin
and 10µg/mL gentamycin) in the presence or absence of Sm-
p80-immunized baboon sera (1:50 dilution) with or without
exogenous complement sera from guinea pig (1:50 dilution)
(Millipore Sigma). Media alone or pooled sera from baboons
receiving adjuvant/vehicle alone were used as controls. Sera
were heat-inactivated by incubating samples at 56◦C for 30min.
Schistosomula were classified as viable or dead on the basis of
motility and morphology (presence of granularity and blebbing)
under light microscopy with 3 technical replicates per group.
RNA Purification and RNA-Sequencing
Total RNA was used for RNA-seq library preparation from
individual baboon samples of PBMCs, spleen cells, and
lymph node cells with three biological replicates and two
technical replicates along with their corresponding controls
for each of the eight vaccine strategies. Total RNA was
extracted using GenElute R© Mammalian Total RNA Miniprep
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Kit (Sigma–Aldrich, St. Louis, MO) following the manufacturer’s
instructions. Total RNA concentrations were quantified via
Qubit R© 3.0 Fluorometer and RNA HS Assay Kit (Thermo
Fisher,Waltham,MA) and RNA quality was determined using the
Agilent 2200 TapStation (Agilent, Santa Clara, CA).
Library preparation was completed as previously described
(31) and stranded mRNA-sequencing on the NovaSeq 6000
platform (Illumina) was fulfilled following standard protocols
by the Texas Tech University Center for Biotechnology and
Genomics (Lubbock, TX).
RNA-Seq Analysis Pipeline
Alignment and determination of differentially expressed
genes (DEGs) were conducted using the Galaxy platform
(www.usegalaxy.org). Briefly, raw reads were aligned to
the human genome (hg19) using HISAT2 (34). Then, read
summarization was completed using the featureCounts program
(35). DEGs were determined from the resultant count tables
using DESeq2 (36).
Downstream pathway analyses on DEGs were completed
based on cut-offs of 1.5-fold change compared to control groups
and P < 0.1. Gene ontology (GO) of both up- and down-
regulated DEGs were analyzed using ClueGo (version 2.5.6)
app on Cytoscape (version 3.7.2) software. DEGs related to
immune system processes were visualized as a network of
GO term clusters with a minimum of 3 genes per cluster
unless otherwise mentioned, represented likewise as a pie
graph depicting percentage of genes per GO group out of the
total number of genes. Pathway analyses were generated with
Ingenuity Pathway Analysis (IPA) (Qiagen, Venlo, Netherlands)
using genes related to immune system processes. Heat maps
depicting gene expression and bar graphs representing Z-scores
and P-values for canonical pathways were generated using
GraphPad Prism (version 7.04).
Selected genes validated via quantitative real-time polymerase
chain reaction (qPCR) as previously described (31). Briefly,
primers were designed from mRNA sequences obtained from
the NCBI for Papio anubis genes. The list of primer sequences
used for qRT-PCR is provided in Supplementary Table 1. Total
RNA from PBMCs, spleen cells, and lymph node cells was
extracted using GenEluteTM Mammalian Miniprep kit (Sigma-
Aldrich, St. Louis, MO, USA) and first strand cDNA synthesis
was completed using the Maxima First Strand cDNA synthesis
kit (Thermo Fisher Scientific). Amplification of selected genes
was carried out using SYBR Premix Ex TaqTM (TIi RNase H Plus;
Takara, Japan) in triplicates on a StepOneTM plus Real-time PCR
system (Thermo Fisher Scientific). Results were analyzed using
DataAssistTM software (version 3.0) (Thermo Fisher Scientific)
(Supplementary Table 2).
Statistical Analysis
Student’s t-tests were used for pairwise comparisons between
groups for the mouse in vivo passive transfer and in vitro
schistosomula killing studies with P < 0.05 indicating statistical
significance. Plotted data represents individual data points with
error bars showing means and standard error of the mean.
Differentially expressed genes were selected based on the cutoff
of P < 0.1 and 1.5-fold change compared to controls for pathway
analyses using IPA and ClueGO.
RESULTS
Reduction in Parasitological Burden
Following Passive Transfer
To assess the protective efficacy of Sm-p80-specific IgG against S.
mansoni infections, mice were passively transferred with purified
Sm-p80-specific IgG from pooled baboon sera as described
above. Passively transferred Sm-p80-specific IgG protected naïve
C56BL/6 mice from S. mansoni challenge infection. Specifically,
we observed significant reduction in adult worm numbers [male
worms: 57.7% (P = 0.0142); female worms: 60.0% (P = 0.0125);
total worms: 58.8% (P = 0.0130)] in experimental mice that
received Sm-p80-specific antibodies when compared to the
control mice (Figure 1A). Liver and intestine tissue samples from
control and experimental groups were also assessed for tissue
egg burden. We observed a significant reduction of 47.9% (P =
0.0468) in liver egg burden in experimental mice when compared
to the control group (Figure 1B). While we also observed a 42.8%
(P = 0.2358) reduction in egg burden within the intestines of the
experimental mice, the reduction was not statistically significant
(Figure 1C).
Reduction in Schistosoma mansoni Egg
Viability in Mouse Tissues
In order to determine egg viability, we compared the hatching
rates of eggs isolated from infected mouse liver and intestine
tissue samples from the control and experimental groups.
Hatching rate analysis of eggs isolated from the tissues of mice
receiving Sm-p80-specific IgG showed a significant reduction of
52.2% (P = 0.0001) in the liver when compared to that of the
control animals (Figure 1D). Similarly, we observed a significant
decrease of 49.6% (P = 0.0001) in egg hatching rates from eggs
isolated from the intestines of mice from experimental group
compared to those from the control group (Figure 1E).
In vitro Killing of Schistosoma
Schistosoma mansoni
Schistosoma mansoni schistosomula were cultured in the
presence of baboon sera with or without exogenous complement.
In the presence of Sm-p80-immunized baboon sera, we observed
a 91.0% killing efficiency (P = 0.0008) of schistosomula in
vitro when compared to control sera. The killing efficacy was
significantly augmented (1.7-fold, P = 0.0006) with the addition
of exogenous complement compared to experimental sera
without modification. The complement-dependent killing effect
was reversed by heat-inactivation (Figure 1F). Interestingly, we
also observed that the control sera with exogenous complement
showed schistosomula killing efficiency comparable to the
experimental sera alone.
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FIGURE 1 | Role of antibodies in Sm-p80-based vaccine-mediated protection. (A) Recovered adult male and female worms following passive transfer of purified IgG
from baboons immunized with Sm-p80-based vaccine. (B) Liver egg burden and (C) intestine egg burden at necropsy. Hatching rates of eggs recovered from livers
(D) and Intestines (E) of mice at necropsy. (F) In vitro killing of S. mansoni schistosomula in the presence of pooled sera from Sm-p80-vaccinated baboons with
addition or absence of exogenous complement. All mice were sacrificed at 6 weeks post S. mansoni cercariae challenge. Plotted data represents individual data
points with error bars showing means and standard error of the mean.
Immune Signatures of Sm-p80-Based DNA
Vaccine
RNA-Seq analysis of gene expression in the PBMCs, spleen cells,
and lymph nodes of baboons vaccinated with different strategies
of Sm-p80-based vaccines revealed diverse immune signatures
depending on the strategy and adjuvant choice. We performed
gene ontology (GO) enrichment analysis to first determine which
DEGs were related to immune system processes. GO terms reveal
the processes to which the DEGs belong and the connection of
processes which are represented by linked clusters of GO terms
(Supplementary Figures 1–32).
Sm-p80-VR1020 was a DNA vaccine formulation which
conferred 46% reduction in worm burden in baboons compared
to controls (22). Four weeks after vaccination and prior to
challenge, 270 genes related to immune system processes
were differentially expressed in the PBMCs. These genes
belonged to GO groups such as hemopoiesis (15.69%), leukocyte
differentiation (10.42%), immunoglobulin production involved
in immunoglobulin mediated immune response (5.28%), and
others (Figure 2A top). These DEGs were inputted into IPA
to predict activation (positive) or deactivation (negative) based
on the Z-score, a composite of the degree of overlap between
directional expression of genes from the observed data and
the QIAGEN-curated public database. The pathways at this
time point with the highest statistical significance include the
neuroinflamation signaling pathway (Z-score = −0.853), iCOS-
iCOSL signaling in T helper cells (Z-score = 1.508), and Th2
pathway (Z-score = 1.667) (Figure 2A bottom). Interestingly,
the hepatic fibrosis signaling pathway was predicted to be
deactivated (Z-score = −0.894) prior to parasite challenge.
Predicted activation of the CD28 signaling in T helper cells
pathway (Z-score = 2.449) and iCOS-iCOSL signaling in T
helper cells pathway may explain why DEGs belonging to
the immunoglobulin production involved in immunoglobulin
mediated immune response GO group were the third highest
group at 5.28% out of a total of 270 genes. High Sm-p80-specific
IgG titers were previously correlated to protect baboons with this
DNA vaccine strategy (22).
After schistosome parasite challenge and prior to sacrifice,
blood was drawn and PBMCs were isolated for RNA-Seq analysis
on baboons vaccinated with the DNA vaccine Sm-p80-VR1020
(Figure 2B top). At this time point, myeloid cell activation
involved in immune response (24.67%), immune response-
activating cell surface receptor signaling pathway (15.86%),
and IFNγ-mediated signaling pathway (14.1%) were the top
GO groups represented by the 137 DEGs (Figure 2B top).
IPA predicted activation of pathways including dendritic cell
maturation (Z-score = 2.309), role of pattern recognition
receptor (PRR) recognition of bacteria and viruses (Z-score =
0.816), T cell exhaustion signaling pathway (Z-score = 1), and
the Th2 pathway (Z-score = 1) (Figure 2B bottom). IPA also
predicted involvement of the complement system (Z-score = 1)
as well as the Th1 pathway (Z-score= 1.633).
At sacrifice, spleen and lymph node cells were collected
for RNA-Seq analysis. The top GO groups for spleen cells
include hemopoiesis (21.82%), leukocyte activation involved
in immune response (20.85%), and dendritic cell chemotaxis
(14.33%) (Figure 2C top). From these immune system process-
associated DEGs, the canonical pathways predicted withmost the
statistical significance include PKCθ signaling in T lymphocytes
(Z-score= 0.632), CD28 signaling in T helper cells (Z-score= 1),
hepatic fibrosis signaling pathway (Z-score = 1.265), NF-kB
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FIGURE 2 | RNA-Seq analysis of Sm-p80-VR1020, a DNA vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment analysis represented as a
pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P < 0.01, respectively.
(Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted activation (red) and
deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of genes from the
observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge (Top) Gene
ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis. (Bottom)
Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. Bottom) Canonical pathway analysis
generated using IPA.
activation by viruses (Z-score = 1.633), and role of NFAT
in regulation of the immune response (Z-score = 0.378)
(Figure 2C bottom). Interestingly, both Th1 and Th2 pathways
were predicted to be activated in the spleen. RNA-Seq analysis of
lymph nodes revealed 18 immune system process-related DEGs
with no predicted canonical pathways that were statistically
significant (Figure 2D).
Immune Signatures of Sm-p80-Based DNA
Prime/Protein Boost Vaccine With CpG
ODN
The second Sm-p80-based vaccine strategy used in this study
was DNA prime with Sm-p80-VR1020 and protein boost with
recombinant Sm-p80 and CpG ODN10104, a TLR9 agonist
which resulted in 47.34% reduction of adult worms in vaccinated
baboons compared to controls. After vaccination and prior to
parasite challenge, 316 DEGs related to immune system processes
were detected in the PBMCs. The GO groups with the largest
percentage of these genes were hemopoiesis (16.24%), leukocyte
activation involved in immune response (13.13%), and TLR9
signaling pathway (8.41%) (Figure 3A top). Many of the top
statistically significant canonical pathways were predicted to
be deactivated, including iCOS-iCOSL signaling in T helper
cells, CD28 signaling in T helper cells, and the role of NFAT
in regulation of the immune response (Figure 3A bottom). At
this time point, Th1 and Th2 pathways were predicted to be
deactivated while the IL-23 signaling pathway, crucial to the Th17
pathway, was predicted to be activated.
Prior to sacrifice, we detected 205 DEGs in the PBMCs
compared to control animals. The top GO groups at this
time point include hemopoiesis (26.27%), leukocyte activation
involved in immune response (18.31%), T cell receptor signaling
pathway (11.33%), and T cell mediated immunity (6.75%)
(Figure 3B top). While several of the top canonical pathways
did not change direction, such as iCOS-iCOSL signaling in T
helper cells, CD28 signaling in T helper cells, and the role of
NFAT, the prediction for the Th1 pathway (Z-score = 0.728)
and B cell receptor signaling (Z-score = 2.673) converted to
activation (Figure 3B bottom). Production of nitric oxide and
reactive oxygen species in macrophages and iNOS signaling
became among the top 30 most significant canonical pathways
and both were strongly predicted to be activated.
GO enrichment analysis of the spleen cells revealed similar
representation of the top groups, including hemopoiesis
(28.95%), leukocyte activation involved in immune response
(24.34%), and immune response-activating cell surface receptor
signaling pathway (18.42%) (Figure 3C top). Likewise, the top
statistically significant pathways include CD28 signaling in T
helper cells, iCOS-iCOSL signaling in T helper cells, leukocyte
extravasation signaling, and the Th2 pathway, all of which were
predicted to be deactivated (Figure 3C bottom). Gene expression
from lymph node cells revealed different immune signatures
compared to those found from PBMCs and spleen cells. Besides
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FIGURE 3 | RNA-Seq analysis of Sm-p80-VR1020 + rSm-p80+ODN10104, a prime/boost vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology
enrichment analysis represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P <
0.05 and P < 0.01, respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on
predicted activation (red) and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional
expression of genes from the observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs
after challenge (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment
analysis. (Bottom) Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical
pathway analysis generated using IPA.
hemopoiesis, leukocyte activation involved in immune response,
and immune response-activating cell surface receptor signaling
pathway, GO enrichment analysis indicated T cell differentiation
(5.7%), pro-B cell differentiation (4.35%) as among the highest
represented GO groups out of 306 DEGs related to immune
system processes (Figure 3D top). The DEGs in the lymph
nodes also revealed the involvement of different canonical
pathways compared to PBMCs and spleen cells in this strategy.
For example, the complement system (Z-score = 1.342) and
the hepatic fibrosis signaling pathway (Z-score = 1.528) were
predicted to be activated.
Immune Signatures of Sm-p80-Based DNA
Prime/Protein Boost Vaccine With
Resiquimod
Resiquimod used as the adjuvant component of the Sm-p80-
based vaccine in a DNA prime/protein boost strategy resulted
in 37.62% reduction in schistosome worm burden (30). The
efficacy of this vaccine strategy was lower on the spectrum
of Sm-p80-based vaccines and may explain the relatively low
number of DEGs related to immune system processes from
PBMCs after vaccination but prior to parasite challenge. The
majority of these genes belong to the GO groups leukocyte
activation involved in immune response (39.5%), hemopoiesis
(33.61%), T cell differentiation in thymus (9.24%), and dendritic
cell differentiation (5.88%) (Figure 4A top). Pathway analysis
using IPA revealed relatively few significant pathways including
HOTAIR regulatory pathway (Z-score= 1.134), colorectal cancer
metastasis signaling (Z-score = 0.378), neuroinflammation
signaling pathway (Z-score = −1.134), and glioblastoma
multiforme signaling (Z-score = −0.447) (Figure 4A bottom).
The DEGs driving the predictions for these pathways primarily
include matrix metallopeptidases and Wnt family members.
After parasite challenge, the top GO groups in PBMCs
include myeloid leukocyte mediated immunity (30.36%), T
cell differentiation involved in immune response (19.64%),
and innate immune response activating cell surface receptor
signaling pathway (16.96%) (Figure 4B top). IPA analysis
revealed that pathways related to PCKθ signaling including role
of NFAT (Z-score = 0.707) and NF-kB signaling (Z-score =
1.342) were predicted to be deactivated (Figure 4B bottom).
Interestingly, complement systemwas predicted to be deactivated
(Z-score = −2), possibly correlating with the reduced worm
burden reduction of this strategy compared to other Sm-p80
vaccine strategies.
RNA-Seq and GO enrichment analysis on spleen cells
indicated that the top GO groups were myeloid cell activation
involved in immune response (23.75%), lymphocyte activation
involved in immune response (15.54%), leukocyte differentiation
(9.38%) and complement activation, alternative pathway (8.5%)
(Figure 4C top). Although we see that 8.5% of the 174
DEGs related to immune system process belong to the
complement activation GO group, IPA analysis revealed that the
complement system pathway was predicted to be deactivated
(Z-score = −1.633) with the highest statistical significance
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FIGURE 4 | RNA-Seq analysis of Sm-p80-VR1020 + rSm-p80+Resiquimod, a prime/boost vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology
enrichment analysis represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P <
0.05 and P < 0.01, respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on
predicted activation (red) and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional
expression of genes from the observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs
after challenge (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment
analysis. (Bottom) Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical
pathway analysis generated using IPA.
compared to other canonical pathways. Other significant
pathways predicted to be deactivated include neuroinflammation
signaling pathway (Z-score = −2.5), TREM1 signaling (Z-score
= −3), IL-8 signaling (Z-score = −2.887), and NF-kB signaling
(Z-score = −1.897) (Figure 4C bottom). The top GO groups
for lymph node cells were leukocyte differentiation (15.16%),
leukocyte activation involved in immune response (12.82%), and
hemopoiesis (12.54%) (Figure 4D top). Similar to the PBMCs
and spleen cells, IPA predictions for PCKθ-related signaling were
deactivation, including NF-kB signaling (Z-score = −1.414),
CD28 signaling (Z-score = −0.447), and iCOS-iCOSL signaling
(Z-score = −1) (Figure 4D bottom). Interestingly, the hepatic
fibrosis signaling pathway was predicted to be deactivated at both
time points for PBMCs and for spleen and lymph node cells with
this vaccine strategy.
Immune Signatures of Sm-p80-Based
Protein Vaccine With CpG ODN
Compared to the DNA prime/protein boost strategy with CpG
ODN, the recombinant protein vaccine strategy with CpG ODN
conferred higher worm burden reduction at 57% compared to
control animals (30). Using PBMCs obtained after vaccination,
the top GO groups from which the immune system process-
related DEGs belong include myeloid cell activation involved
in immune response (32.78%), hemopoiesis (23.16%), pattern
recognition receptor signaling pathway (9.04%), and T cell
proliferation (7.91%) (Figure 5A top). Although the IFNγ-
mediated signaling pathway was represented in the GO analysis
through differential expression of IL-12 receptor subunit β1,
there was insufficient data to predict activation or deactivation
of the Th1 pathway. Similarly, Th2 and Th17 pathways were
unable to be predicted (Figure 5A bottom). Instead, the top
canonical pathways for PBMCs after vaccination and prior to
parasite challenge were colorectal cancer metastasis signaling
(Z-score = −0.277), hepatic fibrosis signaling pathway (Z-
score = −1), leukocyte extravasation signaling (Z-score =
−0.378), and IL-8 signaling (Z-score=−0.707), all of which were
predicted to be deactivated.
From the 69 DEGs related to immune system processes
identified in the PBMCs after parasite challenge, the top
GO groups were T cell activation (38.95%), leukocyte
differentiation (18.58%), innate immune response-activating
signal transduction (11.5%), and antimicrobial humoral response
(8.85%) (Figure 5B top). The top pathways that IPA predicted
to be activating based on these DEGs include TREM1 signaling
(Z-score = 2.449), NF-kB signaling (Z-score = 1.342), and
neuroinflammation signaling pathway (Z-score = 2.236) driven
by upregulation of DEGs such as TLR8, TLR9, TLR10, PLCG2,
and others (Figure 5B bottom). The top pathways predicted
to be deactivated were systemic lupus erythematosus in B cell
signaling pathway (Z-score=−0.333), melanocyte development
and pigmentation signaling (Z-score = −1), and phospholipase
C signaling (Z-score = −0.447) mainly elicited by TNF family
regulators, LAT, and PLCG2.
From the spleen, only 19 DEGs were related to immune
system processes and these belong to GO groups such as cellular
response to IFNγ (45.0%), natural killer cell activation (15.0%),
and B cell response involved in immune response (15.0%).
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FIGURE 5 | RNA-Seq analysis of rSm-p80+ODN10104, a recombinant protein vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment
analysis represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P <
0.01, respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted
activation (red) and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of
genes from the observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge
(Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis.
(Bottom) Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway
analysis generated using IPA.
These few DEGs were insufficient to predict the direction of
any canonical pathways (Figure 5C). The lymph nodes reveal
much more about this vaccine strategy with 314 DEGs related to
immune system processes. The majority of these DEGs belong
to the following GO groups: hemopoiesis (18.44%), leukocyte
activation involved in immune response (16.88%), antigen
processing and presentation of exogenous peptide antigen
(15%), and somatic diversification of immunoglobulins (8.91%)
(Figure 5D top). The top canonical pathways predicted to be
deactivated include ovarian cancer signaling (Z-score = −1),
colorectal cancer metastasis signaling (Z-score = −1.941), and
acute myeloid leukemia signaling (Z-score=−1.414), associated
with Wnt family genes, RAS family genes, and SRC family
kinases. Chemokine signaling (Z-score = 0.707), synaptogenesis
signaling pathway (Z-score = 0.535), and VEGF signaling (Z-
score = 0.447) were the top canonical pathways predicted to be
activated by IPA (Figure 5D bottom).
Immune Signatures of Sm-p80-Based
Protein Vaccine With Resiquimod
The fifth strategy from which samples were obtained in this study
was recombinant Sm-p80 formulated with Resiquimod (30),
yielding higher reduction in worm burden than its prime/boost
counterpart at 52.10% compared to controls in the baboon
model. Using PBMCs obtained after vaccination and prior
to parasite challenge, RNA-Seq analysis indicated 224 DEGs
related to immune system processes. Most of these DEGs fall
under GO groups such as granulocyte activation (15.95%),
hemopoiesis (15.59%), leukocyte differentiation (11.29%), type
I interferon signaling pathway (6.09%), and innate immune
response activating cell surface receptor signaling pathway
(10.93%) (Figure 6A top). Some of the canonical pathway
with highest statistical significance were predicted to be in the
opposite direction in this protein vaccine strategy compared
to the prime/boost strategy with Resiquimod, including hepatic
fibrosis signaling pathway (Z-score = 1.147), NF-kB signaling
(Z-score = 1.155), and systemic lupus erythematosus in B cell
signaling pathway (Z-score = 0.535). Interferon signaling (Z-
score = 1), PKCθ signaling in T lymphocytes (Z-score = 0.333),
Toll-like receptor signaling (Z-score = 1.633), IL-6 signaling (Z-
score = 0.378), and IL-8 signaling (Z-score = 1.414) are other
notable canonical pathways were predicted to be activated due to
the effect of vaccination alone (Figure 6A bottom).
After parasite challenge, GO enrichment analysis of PBMCs
indicated that DEGs fell into groups such as follicular B
cell differentiation (19.47%), neutrophil activation (18.95%),
immune response-activating cell surface receptor signaling
pathway (9.82%), and type I interferon signaling pathway
(7.89%) (Figure 6B top). IPA predictions for several canonical
pathways did not differ in direction compared to the previous
time point, including systemic lupus erythematosus in B cell
signaling pathway (Z-score = 1.732), hepatic fibrosis signaling
pathway (Z-score = 0.894), Toll-like receptor signaling (Z-
score = 1.633), interferon signaling (Z-score = 3), and NF-
kB signaling (Z-score = 0.258). Notably, the Th1 pathway (Z-
score = 0.333) was predicted to be activated while the Th2
pathway (Z-score = −1.633) was predicted to be deactivated
(Figure 6B bottom).
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FIGURE 6 | RNA-Seq analysis of rSm-p80+Resiquimod, a recombinant protein vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment
analysis represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P <
0.01, respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted
activation (red) and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of
genes from the observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge
(Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis.
(Bottom) Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway
analysis generated using IPA.
Unlike the prime/boost vaccine strategy using Resiquimod,
the recombinant protein vaccine with Resiquimod had a minor
effect on the transcriptome of spleen cells with only 19 DEGs
identified. The largest GO groups for the spleen cell DEGs
included type I interferon signaling pathway (34.62%), antigen
processing and presentation of endogenous peptide antigen
via MHC class I via ER pathway (30.7%), and macrophage
activation (11.54%) (Figure 6C top). The only significant
canonical pathway predicted by IPA was neuroinflammation
signaling pathway (Z-score = 2.236) which was associated
with upregulation in MHC I isotypes A and B, IFNγ receptor
2, TGFβ receptor 3, and VCAM1 (Figure 6C bottom). The
response in the mesenteric lymph nodes was much more robust
than the spleen with 302 DEGs related to immune response
processes. The top GO groups representing these DEGs include
myeloid cell differentiation (12.88%), lymphocyte differentiation
(12.18%), leukocyte activation involved in immune response
(11.24%), myeloid leukocyte differentiation (10.77%), and
B cell activation involved in immune response (4.92%)
(Figure 6D top). Unlike the predictions in the PBMCs after
parasite challenge, NF-kB signaling in lymph node cells was
predicted to be deactivated (Z-score = −1.043). However,
predictions for some canonical pathways remained in the same
direction, including neuroinflammation signaling pathway (Z-
score = 1.177), Toll-like receptor signaling (Z-score = 2.121),
systematic lupus erythematosus in B cell signaling pathway (Z-
score = 0.426), and B cell receptor signaling (Z-score = 0.707)
(Figure 6D bottom).
Immune Signatures of Sm-p80-Based
Protein Vaccine With GLA-AF
The sixth vaccine strategy assessed in this study was recombinant
Sm-p80 formulated with glucopyranosyl lipid adjuvant (GLA)
as an aqueous formulation (AF), resulting in a worm burden
reduction of 28.39% (unpublished data). To explore why this
strategy had relatively low efficacy, we performed RNA-Seq
on PBMCs after vaccination. From the differential expression
of 95 genes related to immune system processes, the top
GO groups at this time point included B cell activation
(26.97%), myeloid leukocyte mediated immunity (18.42%),
antigen receptor-mediated signaling pathway (17.76%), and T
cell mediated immunity (11.18%) (Figure 7A top). At first glance,
these GO groups do not seem vastly different than previous
strategies. However, IPA predictions show that the top canonical
pathways were all pointing toward deactivation, including iCOS-
iCOSL signaling in T helper cells (Z-score = −1.342), Th1
pathway (Z-score = −2.449), dendritic cell maturation (Z-
score = −1.633), and B cell receptor signaling (Z-score =
−2.449) (Figure 7A bottom).
After parasite challenge, the transcriptome PBMCs reflect
a similar immune response to the previous time point, albeit
with more DEGs related to immune system processes. These
426 genes are represented largely by the following GO groups:
hemopoiesis (20.41%), leukocyte activation involved in immune
response (17.05%), antigen receptor-mediated signaling pathway,
antigen processing and presentation of peptide antigen via MHC
class II (11.28%), and B cell activation (7.68%) (Figure 7B
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FIGURE 7 | RNA-Seq analysis of rSm-p80+GLA-AF, a recombinant protein vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment analysis
represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P < 0.01,
respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted activation (red)
and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of genes from the
observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge (Top) Gene
ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis. (Bottom)
Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis
generated using IPA.
top). While the majority of the top canonical pathways were
predicted to be deactivated, some pathways predicted to be
activated include T cell exhaustion signaling pathway (Z-
score = 1.155), PD-1, PD-L1 cancer immunotherapy pathway
(Z-score = 1.387), calcium-induced T lymphocyte apoptosis
(Z-score = 0.302), and interferon signaling (Z-score = 0.378)
(Figure 7B bottom).
GO enrichment analysis of the spleen cells revealed that
the 122 DEGs related to immune system processes belong
to GO groups such as hemopoiesis (22.63%), myeloid cell
activation involved in immune response (13.87%), leukocyte
differentiation (12.77%), thymic T cell selection (10.58%), and
response to IFNγ (6.57%) (Figure 7C top). Again, most of
the canonical pathways were predicted to be deactivated,
including Th1 pathway (Z-score = −1.414), Th2 pathway (Z-
score = −0.816), cytotoxic T lymphocyte-mediated apoptosis of
target cells (Z-score = −2), and crosstalk between dendritic cells
and natural killer cells (Z-score = −1.89). Conspicuously, the
complement system was predicted to be activated (Z-score = 2)
(Figure 7C bottom).
The mesenteric lymph nodes were processed for RNA-
Seq analysis and 75 DEGs were identified that were related
to immune system processes. These genes belonged to GO
groups such as neutrophil activation (31.03%), leukocyte
differentiation (26.72%), T cell differentiation (10.34%), and
response to IFNγ (10.34%) (Figure 7D top). Interestingly,
pathway analysis with IPA predicted that all canonical
pathways related to these DEGs of immune function were
activated including neuroinflammation signaling pathway
(Z-score = 1.667), leukocyte extravasation signaling (Z-
score = 0.447), dendritic cell maturation (Z-score = 1),
and hepatic fibrosis signaling pathway (Z-score = 1.342)
(Figure 7D bottom).
Immune Signatures of Sm-p80-Based
Protein Vaccine With GLA-Alum
Historically, we have observed that a mixed and balanced
immune response between Th1, Th2, and Th17 provided the
highest levels of protection, aligning with studies done by
others (37, 38). Hence, with aluminum hydroxide (Alum)
as the adjuvant, we sought to explore whether tuning the
immune response toward a balanced response would enhance
protection against S. mansoni. We previously reported that this
recombinant protein vaccine strategy provided 38.53% reduction
in worm burden in baboons compared to the control group
which only received the adjuvant alone (32). Surprisingly,
only 10 genes related to immune system processes were
differentially expressed in the PBMCs after vaccination. These
genes fell under the following GO groups: antigen processing
and presentation of exogenous peptide antigen via MHC class
I, TAP-dependent (36.36%), CD4-positive, alpha-beta T cell
differentiation (18.18%), antigen processing and presentation
of endogenous peptide antigen (18.18%), and others. Pathway
analysis with IPA did not reveal any significant predictions for
canonical pathways related to the immune response at this time
point (Figure 8A).
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FIGURE 8 | RNA-Seq analysis of rSm-p80+GLA-Alum, a recombinant protein vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment analysis
represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P < 0.01,
respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted activation (red)
and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of genes from the
observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge (Top) Gene
ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis. (Bottom)
Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis
generated using IPA.
Following parasite challenge and disease progression, 502
DEGs related to immune system processes were identified in
the PBMCs, a drastic increase from the previous time point.
The majority of these DEGs were categorized in GO groups
such as leukocyte activation involved in immune response
(13.11%), hemopoiesis (11.97%), T cell receptor signaling
pathway (11.10%), leukocyte differentiation (9.62%), alpha-beta
T cell activation (8.94%), antigen immune response-activating
signaling pathway (7.67%), and many others (Figure 8B top).
Pathway analysis using IPA revealed nuanced predictions for
the immune response, including activation of the Th1 pathway
(Z-score = 0.832) and deactivation for the Th2 pathway (Z-
score = −0.632) and Th17 pathway (Z-score = −0.728)
(Figure 8B bottom).
The spleen and mesenteric lymph nodes did not reveal many
differentially expressed immune genes with a total of only 3 and 8
identified, respectively. For the spleen cells, these 3 DEGs related
to immune system processes were placed into 3 groups: thymic T
cell selection (50.0%), macrophage cytokine production (25.0%),
and gamma-delta T cell differentiation (25.0%) (Figure 8C). The
eight DEGs from the lymph node cells were also represented
with 3 groups: antigen processing and presentation of exogenous
peptide antigen via MHC class I, TAP-dependent (55.56%),
somatic recombination of immunoglobulin gene segments
(33.33%), and immunoglobulin V(D)J recombination (11.11%)
(Figure 8D). IPA was unable to predict the direction of any
pathways for the DEGs from the spleen and lymph nodes for this
vaccine strategy.
Immune Signatures of Sm-p80-Based
Protein Vaccine With GLA-SE
Recombinant Sm-p80 formulated with GLA-SE (31)
demonstrated the highest levels of protection among the
vaccine strategies tested. The latest studies using this vaccine
strategy was reported to have female worm reduction of 93.35%
and overall worm burden reduction of 65.90%. To examine the
effects of the vaccine, we performed RNA-Seq analysis on PBMCs
after the vaccination regimen. We identified 229 DEGs related to
immune system processes. These genes were found in GO groups
such as hemopoiesis (19.12%), leukocyte activation involved in
immune response (16.81%), B cell activation (10.5%), and others
(Figure 9A top). Eight of the top 30 canonical pathways in terms
of statistical significance were predicted to be activated, including
neuroinflammation signaling pathway (Z-score = 1.069), Toll-
like receptor signaling (Z-score = 0.378), and IL-8 signaling
(Z-score = 0.333). Among the canonical pathways predicted
to be deactivated were colorectal cancer metastasis signaling
(Z-score = −1.5), NF-kB signaling (Z-score = −1.604), B cell
receptor signaling (Z-score = −1), dendritic cell maturation
(Z-score = −0.905), and the Th1 pathway (Z-score = −0.378)
(Figure 9A bottom).
Prior to sacrifice, fewer genes were differentially expressed
in the PBMCs. These 74 DEGs related to immune system
processes were categorized in GO groups such as myeloid
leukocyte mediated immunity (44.66%), leukocyte differentiation
(22.33%), Toll-like receptor signaling pathway (13.59%), and
Fc receptor-mediated stimulatory signaling pathway (7.77%)
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FIGURE 9 | RNA-Seq analysis of rSm-p80+GLA-SE, a recombinant protein vaccine strategy. (A) PBMCs after vaccination (Top) Gene ontology enrichment analysis
represented as a pie graph of percentages of genes per group out of a total number of differentially expressed genes. “**” and “*” indicates P < 0.05 and P < 0.01,
respectively. (Bottom) Canonical pathway analysis generated using IPA. Bars are plotted based on the – log10(P-value) and colored based on predicted activation (red)
and deactivation/inhibition (blue) according to the Z-score, a composite assessment based on the degree of overlap between directional expression of genes from the
observed data and the Qiagen-curated public database. The top 30 pathways are shown based on the lowest P-values. (B) PBMCs after challenge (Top) Gene
ontology enrichment analysis. (Bottom) Canonical pathway analysis generated using IPA. (C) Spleen cells (Top) Gene ontology enrichment analysis. (Bottom)
Canonical pathway analysis generated using IPA. (D) Mesenteric lymph node cells (Top) Gene ontology enrichment analysis. (Bottom) Canonical pathway analysis
generated using IPA.
(Figure 9B top). Accordingly, fewer pathways were able to be
predicted with statistical significance. Canonical pathways that
were predicted to be activated include role of PRR in recognition
of bacteria and viruses (Z-score= 0.378), FCγ receptor-mediated
phagocytosis in macrophages and monocytes (Z-score = 0.447),
dendritic cell maturation (Z-score= 1), hepatic fibrosis signaling
pathway (Z-score= 1.342), and role of NFAT in regulation of the
immune response (Z-score= 2) (Figure 9B bottom).
Spleen cells were processed for RNA-Seq and 122 DEGs
related to immune system processes were accepted after cutoffs.
These DEGs were represented in the following GO groups:
lymphocyte differentiation (16.61%), hemopoiesis (15.55%),
myeloid cell activation involved in immune response (12.72%),
T cell differentiation (6.36%), and others (Figure 9C top).
Only 3 of the top 30 canonical pathways were predicted to
be activated according to pathway analysis by IPA: T cell
exhaustion, apelin endothelial signaling pathway, and PD-1,
PDL1 cancer immunotherapy pathway. Some notable pathways
that were predicted to be deactivated include the Th1 pathway
(Z-score = −0.816), Th2 pathway (Z-score = −0.816), and
pathways related to PKCθ signaling such as NF-kB signaling (Z-
score = −1.414), CD28 signaling (Z-score = −2.236), iCOS-
iCOSL signaling (Z-score = −2.646), and role of NFAT (Z-score
=−1.342) (Figure 9C bottom).
The mesenteric lymph node cells yielded 306 DEGs related
to immune system processes. The largest GO groups for
these DEGs include lymphocyte differentiation (12.92%), B
cell activation (11.52%), myeloid cell differentiation (10.78%),
and hemopoiesis (10.78%) (Figure 9D top). Many canonical
pathways were predicted to have the same direction as those for
spleen cells, including Th1 pathway (Z-score = −1.807), Th2
pathway (Z-score = −1.732), and pathways related to PKCθ
signaling. Notably, the complement system was predicted to be
activated in the lymph node cells with this strategy (Z-score= 2)
(Figure 9D bottom).
DISCUSSION
The complexity of schistosomiasis, socio-economic implications
notwithstanding, demand nuance, and discretion to solve.
Schistosomes have co-existed and co-evolved with mankind for
millennia and they invariably have honed their abilities to evade
attacks by our immune response. Indeed, schistosomes do not
simply avoid detection but can thrive in their host for decades
(39), actively modulating our immune response to propagate
their life cycle (40). Two of the “grails” of vaccinology for
schistosomiasis would be to find a universal immune signature
to predict protection or to define a surrogate of protection. As of
yet, no universal immune signature nor surrogate of protection
has been defined or agreed upon for schistosomiasis.
As a follow-up from eight previous vaccine studies, we
assessed the killing effect of immune sera from Sm-p80-
vaccinated baboons on S. mansoni schistosomula in vitro.
Our results showed a significant schistosomula killing when
cultured in the presence of sera obtained from Sm-p80-
vaccinated baboons when compared to sera from control
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baboons and the killing effect was significantly augmented with
the addition of exogenous complement. Our data also showed
that the complement effect was completely reversed when heat
inactivated. Cumulatively, these data strongly suggest possible
roles for Sm-p80-specific antibodies, complement and/or both in
vaccine-mediated parasite killing. The parasite killing observed is
not surprising as we have previously shown that Sm-p80 protein
is highly expressed on the surface of S. mansoni schistosomula
(25), presenting multiple target epitopes for antibodies. We
further explored the in vivo protective role of these Sm-p80
antibodies against S. mansoni in a mouse model of infection
and disease. In the experimental group, heterologous transfer
of purified IgG from baboons immunized with Sm-p80-based
vaccine conferred significant protection in mice following S.
mansoni cercarial challenge. Specifically, we observed a 59%
reduction in total worm numbers from experimental mice that
received purified Sm-p80-specific IgG when compared to the
control mice. More importantly, there was a 60% reduction
in total egg-producing female worms from these experimental
mice suggesting that Sm-p80-specific IgG might be selectively
killing female worms. This is in agreement with our previous
preclinical efficacy study in which we also observed significant
female worm killing in baboons immunized with Sm-p80
vaccine (32).
The pathology of schistosomiasis and its severity is directly
linked to the number of schistosome eggs trapped within the host
tissues, particularly the liver, and the host immune responses to
antigens secreted by viable eggs within these tissues (3, 41). In
this study, we found that passively transferred Sm-p80-specific
IgG lead to a significant reduction in hepatic and intestinal egg
load in mice compared the control group, demonstrating anti-
pathology effect of anti-Sm-p80-specific antibodies. In addition
to the observed reduction in tissue egg burden, we also observed
a significant reduction in egg viability/hatching rates in eggs
obtained from the liver and a moderate reduction in egg hatching
rates in eggs obtained from the intestines. Specifically, liver
and intestinal eggs recovered from experimental mice had a
49.6 and 42.8% reduction in hatching rates, respectively. Taken
together, the data presented here on Sm-p80-specific IgG-
mediated female worm killing, reduction in tissue egg burden,
and reduction in egg hatching highlight not only the anti-
pathology effect of Sm-p80 antibodies but also its potential at
reducing transmission as fewer viable eggs are released into the
environment (42, 43).
Exploration of the immune response through the lens of
transcriptomic analyses revealed a kaleidoscopic range of results.
Initially, we overlaid the DEGs from each vaccine strategy to
determine whether we could identify any genes that would be
differentially expressed consistently. While we certainly found
common DEGs between various strategies, no DEGs were
common among all eight strategies (Supplementary Figure 33).
We subsequently examined the relationship between the DEGs
of various strategies with their respective GO groups. Categories
of gene ontology displayed some similarity. For example, we
found evidence for prominent T cell and B cell responses in every
strategy; while particular components of the immune response
may not be reflected on GO groups in one tissue, they would
appear in another. Interestingly, we found that hemopoiesis
was one of the largest GO groups for each time point and
tissue type, appearing in seven out of the eight strategies in
the PBMCs after vaccination. After parasite challenge, we found
that the hemopoiesis GO group was more represented in the
spleen and lymph nodes compared to PBMCs. Hemopoiesis,
defined broadly as the process by which immune progenitor
cells develop into mature cells with varying though distinct
lineages, has implications for vaccine-based immune responses
and subsequent protective efficacy to said vaccines (44, 45).
Perturbations in the immune response via vaccines or pathogens
elicit cytokines, growth factors, and other signaling pathways that
affect the regulation of hematopoietic stems cells (HSCs) (46).
Based on differential expression of members of the Wnt family,
the Wnt signaling cascade may be a key regulator for HSCs
and hemopoiesis in response to Sm-p80-based vaccines, although
the exact mechanism linking hemopoiesis to schistosome worm
burden reduction is unknown.
We observed much evidence for involvement of cellular
immune responses, especially DEGs related to T cells,
corroborating our previous reporting based on analyses
with PCR, ELISPOT, and flow cytometry (22, 30–32). Through
RNA-Seq analyses, we have found that protein Kinase C-theta
(PKCθ) signaling in T helper cells play a role in Sm-p80-induced
cellular immunes. PKCθ has been described to balance regulatory
T cell (Tregs) and effector T cell functions through a range of
signaling cascades (47, 48). These signaling cascades include
CD28 signaling (49), iCOS-iCOSL signaling (50), NFAT (51),
and NF-kB (52). CD28 is a costimulatory factor critical for
the induction of MHC class II-restricted T cell responses and
bridges the humoral response through CD80 (53, 54). Indeed,
others have shown that CD28 costimulation is important in
mounting an appropriate response to S. mansoni infection
through the use of CD28-deficient (–/–) mice which produced
reduced levels of parasite-specific IgG1 and IgE antibodies
compared to wild-type animals (55). The inducible co-stimulator
(iCOS) and its ligand, iCOSL, have a range of functions that
include the regulation of T helper cells, cytokine production, T
cell/ B cell collaboration through CD40/CD40L pathway, and
immunoglobulin class switching (56, 57). While the iCOS-iCOSL
pathway has been reported to have an effect on fibrosis and
hepatopathology in mice infected with schistosomiasis, its
exact role is debated (58, 59). The nuclear factor of activated
T cells (NFAT) pathway is known to regulate T cell activation,
differentiation, and development (60). Others have demonstrated
that NFAT−/− mice have increased eosinophil and serum levels
of IgE (61) and that NFAT family proteins positively regulate
IL-4 production (62), suggesting that NFAT may play a role in
the Th2 response in schistosomiasis (63, 64). NF-kB are among
transcription factors that induce IL-2 expression and regulates
inflammatory responses (65). Others have shown that S. mansoni
interferes with the NF-kB pathway, thereby disrupting the
recruitment of leukocyte recruitment to the lungs and allowing
the parasite to evade the immune response (66). Additionally,
it has been suggested that manipulation of NF-kB signaling
may be a method of treating schistosomiasis (67–69). Although
evidence for these pathways were frequently observed from the
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RNA-Seq analysis of the eight different Sm-p80-based vaccine
strategies, their predictions were variable and inconsistent
between strategies.
Ultimately, what we discovered may be unsurprising –
Sm-p80 vaccine-induced signatures of immunity differ based on
the strategy and/or adjuvant used and no universal signatures
of immunity were found. While common pathways were
found in each vaccine strategy, the direction and magnitude
of predictions for these pathways differed without obvious
patterns. This conclusion may be due to several factors to
consider. First, the biological diversity in our studies presents
a dichotomy of benefits and detriments. The baboons used
in Sm-p80-based vaccine studies were outbred with ages
that ranged from 1 year old to 15 years old. Introduction of
biological diversity in our studies would better recapitulate
results when we transition into human clinical trials where the
extent of diversity would increase. However, utilizing outbred
animal models introduce statistical variance which reduces
our ability to distinguish more subtle immune signatures
in which high fold change is biologically unreasonable
to expect. Furthermore the timing of when samples were
collected was optimized for assessment of antibody responses.
Vaccine-induced changes in gene transcription detectable
by RNA-Seq occur as early as one day after immunization
(70–72) yet ethical considerations prevent us from frequent
blood draws or early sacrifices for sample collection.
Nevertheless, systems biology approaches have proven
to be valuable tools in our understanding of the global
transcriptomic effects of Sm-p80-induced protection. Combined
with the previously published results from conventional
immunological techniques, Sm-p80-based vaccines have
consistently demonstrated robust immune responses associated
with protection and is poised to enter Phase I human
clinical trials.
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